Clinical Trials Logo

Alzheimer Disease clinical trials

View clinical trials related to Alzheimer Disease.

Filter by:
  • Available  
  • Page 1

NCT ID: NCT05959239 Available - Alzheimer Disease Clinical Trials

TB006 Expanded Access (EA) Compassionate Use

Start date: n/a
Phase:
Study type: Expanded Access

This is an open-label, expanded access, compassionate use treatment protocol of TB006 treatment in participants who meet clinical diagnostic criteria for Alzheimer's disease (AD). Participants will receive TB006 at a dose of 4,000 milligrams (mg) intravenous (IV) over 1 hour every 28 days ± 5 days.

NCT ID: NCT03539380 Available - Alzheimer Disease Clinical Trials

TRx0237 for the Treatment of Early and Mild-Moderate Alzheimer's Disease

Start date: n/a
Phase:
Study type: Expanded Access

This is an expanded access program (EAP) for eligible participants. This program is designed to provide continued access to TRx0237 to individual patients with early and mild-moderate Alzheimer's disease who do not qualify for participation in an ongoing clinical trial. Eligible participants must have previously completed participation in a clinical trial of TRx0237 conducted by TauRx or have previously taken TRx0237 in a compassionate use program, among other criteria. Patients will be considered where a physician can demonstrate clinical benefit for a patient not meeting these criteria; in these cases, TauRx will consider participation of the patient on a case-by-case basis.